Vivos Therapeutics (VVOS) PT Raised to $2.90 at Ascendiant Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts VVOS Hot Sheet
Price: $0.13 --0%
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Join SI Premium – FREE
Ascendiant Capital analyst Lucas Ward raised the price target on Vivos Therapeutics (NASDAQ: VVOS) to $2.90 (from $2.80) while maintaining a Buy rating.
You May Also Be Interested In
- Standard Chartered Plc. (STAN:LN) (SCBFF) PT Raised to GBP27.90 at Goldman Sachs
- Canaccord Downgrades Botanix Pharmaceuticals Ltd (BOT:AU) to Hold
- Bajaj Auto Ltd (BJAUT:IN) PT Raised to INR12,900 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
